UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2007

SYNVISTA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
 
 
 
 
 
Delaware
 
001-16043
 
13-3304550
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)

221 West Grand Avenue
Montvale, New Jersey 07645
(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (201) 934-5000
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
ITEM 8.01 OTHER EVENTS
 
On October 1, 2007, Synvista Therapeutics, Inc., a Delaware corporation (the “Company”), announced that Dr. Carl Mendel, MD, has joined the Company as its Vice President of Clinical Development and Chief Medical Officer, commencing on October 1, 2007. Dr. Mendel will receive an annual salary of $265,000 and will be eligible to receive an annual cash bonus based on predetermined milestones of up to 20% of his annual salary. In addition, upon commencement of his employment with the Company, Dr. Mendel will be granted options to purchase 70,000 shares of the Company’s common stock at an exercise price equal to the closing price of the common stock on the grant date. Dr. Mendel will be an at-will employee of the Company.
 
A copy of the press release announcing Dr. Mendel’s appointment is attached hereto as Exhibit 99.1 and incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
 
(d)
Exhibits.
   
99.1 Press Release dated October 1, 2007.
 
 
 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
  SYNVISTA THERAPEUTICS, INC.
 
 		  
 		  
 
Dated: October 1, 2007 By:   /s/ Noah Berkowitz, M.D., Ph.D.
 
Noah Berkowitz, M.D., Ph.D.
  President and Chief Executive Officer

 
 
 
 
 
EXHIBIT INDEX
 
Exhibit Number Description
 
 
99.1 Press Release dated October 1, 2007.